1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERSTANDING

1.1 Product identifier
Product Name: Vectibix
Common Name: Panitumumab
Chemical Name: Not Applicable
Synonyms: ABX-EGF, AMG 954, Panitumumab

1.2 Relevant identified uses of the substance or mixture and uses advised against
Recommended Use: Pharmaceutical
Uses advised against: No information available

Manufacturer:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California  91320-1799
1-805-447-7233
1-805-447-1000

Emergency Telephone Number:
Chemtrec
NORTH AMERICA 1-800-424-9300,
INTERNATIONAL 1-703-527-3887

2. HAZARDS IDENTIFICATION

Emergency Overview
Pharmaceutical product intended for clinical and manufacturing purposes only. Product contains Vectibix®, a recombinant human IgG2 monoclonal antibody directed against the EGF receptor, an active pharmaceutical ingredient for treatment of cancer. Dosage from contents may pose a health hazard only if significant absorption occurs (e.g., inhalation after major spill or leak). Avoid inhalation, skin contact, eye contact and accidental ingestion. Does not meet GHS classification criteria and therefore is not classified.

2.1 - Classification of the drug substance or mixture (drug product in final form, not applicable)
REGULATION (EC) No 1272/2008

Not classified

Classification according to EU Directives 67/548/EEC or 1999/45/EC
For the full text of the R phrases mentioned in this Section, see Section 16

2.2 Label elements
Not classified

2.3 Other Hazards  No information available
3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Ingredients: Proprietary information

Chemical Name: Not Applicable

CAS-No: 339177-26-3

Each single-use 5 mL vial contains 100 mg of panitumumab with:

<table>
<thead>
<tr>
<th></th>
<th>CAS Number:</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium acetate</td>
<td>127-09-3</td>
<td>34 mg</td>
</tr>
<tr>
<td>Sodium chloride (NaCl)</td>
<td>7647-14-5</td>
<td>29 mg</td>
</tr>
<tr>
<td>Water for Injection, USP</td>
<td>7732-18-5</td>
<td>---</td>
</tr>
</tbody>
</table>

Each single-use 10 mL vial contains 200 mg of panitumumab with:

<table>
<thead>
<tr>
<th></th>
<th>CAS Number:</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium acetate</td>
<td>127-09-3</td>
<td>34 mg</td>
</tr>
<tr>
<td>Sodium chloride (NaCl)</td>
<td>7647-14-5</td>
<td>29 mg</td>
</tr>
<tr>
<td>Water for Injection, USP</td>
<td>7732-18-5</td>
<td>---</td>
</tr>
</tbody>
</table>

Each single-use 20 mL vial contains 400 mg of panitumumab with:

<table>
<thead>
<tr>
<th></th>
<th>CAS Number:</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium acetate</td>
<td>127-09-3</td>
<td>136 mg</td>
</tr>
<tr>
<td>Sodium chloride (NaCl)</td>
<td>7647-14-5</td>
<td>117 mg</td>
</tr>
<tr>
<td>Water for Injection, USP</td>
<td>7732-18-5</td>
<td>---</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

4.1 Description of first-aid measures

Eye Contact: In the case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

Skin Contact: Wash off immediately with soap and plenty of water removing all contaminated clothes and shoes. Consult a physician if necessary.

Inhalation: Move to fresh air. If symptoms persist, call a physician.

Ingestion: If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

Notes to Physician: Treat symptomatically.
5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Flammable Properties: Not applicable/aqueous solution.

Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

5.2 Special hazards arising from the substance or mixture

Hazardous Combustion Products: No information available.

5.3 Advice for firefighters

Protective Equipment and Precautions for Firefighters: As in any fire, wear self-contained breathing apparatus pressure-demand, NIOSH (approved) and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Spill Procedures: If material is released or spilled, cordon off spill area. Take proper precautions to minimize exposure by using appropriate personal protective equipment in cleaning up a spill. If in powder form, wet down spilled material to minimize airborne dispersion. Soak up material with absorbent e.g., paper towels, and wash spill area thoroughly with appropriate cleaning materials. Dispose of collected material in accordance with applicable waste disposal regulations. Avoid release to the environment.

7. HANDLING AND STORAGE

7.1 Precautions for Safe Handling

Handling and Storage: Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke in work areas. Use adequate ventilation to minimize exposure. Wash hands, face and other potentially exposed areas immediately after handling this material. Remove contaminated clothing prior to entering eating areas. Clean protective equipment thoroughly after each use. Store in a well ventilated area.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

**Occupational Exposure Limit:** No exposure guidelines established by ACGIH, NIOSH or OSHA. Amgen recommends an occupational exposure limit (OEL) of 60 µg/m³ as an 8-hour time weighted average over a 40-hour work week. The OEL is designed as an acceptable airborne concentration of a substance for which it is believed that workers may be repeatedly exposed day after day without adverse health effects. Vectibix® has been classified per Amgen's Hazard Classification System as an Occupational Exposure Band 3 compound (20 µg/m³ - 100 µg/m³).

**Engineering Controls:** When practicable, handle material in enclosed processes or in processes with effective local exhaust ventilation or within a chemical hood.

8.2 Exposure controls

**Personal Protective Equipment**

**Eye/face Protection:** Wear safety glasses with side shields, chemical splash goggles, or safety glasses with side shields and a full-face shield to prevent contact with eyes. The choice of protection should be based on the job activity and potential for exposure to the eyes and face.

**Skin Protection:** Use gloves or other appropriate personal protective equipment if skin contact with formulation is possible. Wear lab coat or other protective over garment if splashing is possible. The choice of protection should be based on the job activity and potential for skin contact.

**Respiratory Protection:** When possible, handle material in enclosed processes or containers. If it is properly handled with effective local exhaust ventilation or containment, respiratory protection may not be needed. For procedures involving larger quantities or dust/aerosol generating procedures such as weighing or a large transfer of liquids, an air-purifying respirator with NIOSH approval for dusts and mists may be needed.

**Other:** Wash hands, face and other potentially exposed areas after handling material (especially before eating, drinking or smoking). Clean protective equipment thoroughly after each use.

8.3 Environmental exposure controls

**Environmental Exposure Controls** Avoid release to the environment.
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Clear colorless liquid (May contain white to translucent proteinaceous Vectibix® particles)</td>
</tr>
<tr>
<td>Physical State</td>
<td>Liquid</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>Approx. 147kD</td>
</tr>
<tr>
<td>Odor</td>
<td>No information available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No information available</td>
</tr>
<tr>
<td>pH</td>
<td>5.8</td>
</tr>
<tr>
<td>Melting Point</td>
<td>Liquid No information available</td>
</tr>
<tr>
<td>Flash Point</td>
<td>Not applicable /aqueous solution</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>No information available</td>
</tr>
<tr>
<td>Lower explosive limit</td>
<td>No information available</td>
</tr>
<tr>
<td>Upper explosive limit</td>
<td>No information available</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>No information available</td>
</tr>
<tr>
<td>Vapor Density (air = 1)</td>
<td>No information available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No information available</td>
</tr>
<tr>
<td>Water Solubility</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Partition Coefficient (log Kow)</td>
<td>No information available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No information available</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

10.1 Reactivity

None

10.2 Chemical stability

Stable

10.3 Possibility of hazardous reactions

None

10.4 Conditions to avoid

None

10.5 Incompatible materials

None

10.6 Hazardous decomposition products

None

10.7 Other information

None
11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute Toxicity: No information available
Skin corrosion/irritation: No information available
Serious eye damage/eye irritation: No information available
Respiratory or skin sensitization: No information available
Germ cell mutagenicity: No information available
Carcinogenicity: No information available
Reproductive toxicity: Even though this does not meet GHS classification, the following data is available: developmental toxicity has been observed from intravenous administration in animal studies.

STOT - single exposure: Even though this does not meet GHS classification, the following data is available: Vectibix® was tested in a single dose safety pharmacology study to evaluate the potential effects on cardiovascular, respiratory, and central nervous system function in cynomolgus monkeys. No evidence of treatment-related effects on these organs was observed.

STOT - repeated exposure: Even though this does not meet GHS classification, the following data is available: Vectibix® was administered IV to cynomolgus monkeys once weekly at doses up to 30 mg/kg for 4, 13, or 26 consecutive weeks. The major and consistent treatment-related findings observed across all toxicity studies were dose-dependent skin rash and diarrhea, ranging from mild to severe which are attributable to the pharmacologic activities of Vectibix®. These effects were completely reversible. Based on therapeutic administration via IV administration, Vectibix® may affect the gastrointestinal system. Diarrhea has been observed in monkeys injected with Vectibix®. Diarrhea, skin, hair and nail toxicity occurs in patients receiving Vectibix® administered via IV administration. Skin rashes have been observed in humans starting at a systemic dose of 0.75 mg/kg. Exposure by accidental injection may cause site reactions. Target organs include: skin, mucosa, eyes, and lungs.

Aspiration Hazard: No information available
12. ECOLOGICAL INFORMATION

12.1 Toxicity
Ecotoxicity effects: No information available

12.2 Persistence and degradability
Persistence/ Degradability: No information available

12.3 Bioaccumulative potential
Bioaccumulation/ Accumulation: No information available

12.4 Mobility in soil
Mobility in Environmental Media: No information available

12.5 Results of PBT and vPvB assessment
Results of PBT and vPvB assessment: No information available

12.6 Other adverse effects
Other Adverse Effects: No information available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods
Waste Disposal Method: Dispose of any waste according to prescribed federal, state, local and competent authority guidelines.

14. TRANSPORT INFORMATION

DOT
Not regulated by U.S. DOT or IATA
15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

<table>
<thead>
<tr>
<th>Inventory</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSCA</td>
<td>-</td>
</tr>
<tr>
<td>EINECS/ELINCS</td>
<td>-</td>
</tr>
<tr>
<td>DSL/NDSL</td>
<td>-</td>
</tr>
<tr>
<td>PICCS</td>
<td>-</td>
</tr>
<tr>
<td>ENCS</td>
<td>-</td>
</tr>
<tr>
<td>CHINA</td>
<td>-</td>
</tr>
<tr>
<td>AICS</td>
<td>-</td>
</tr>
<tr>
<td>KECL</td>
<td>-</td>
</tr>
</tbody>
</table>

Legend
TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
PICCS - Philippines Inventory of Chemicals and Chemical Substances
ENCS - Japan Existing and New Chemical Substances
I ECSC - China Inventory of Existing Chemical Substances
AICS - Australian Inventory of Chemical Substances
KECL - Korean Existing and Evaluated Chemical Substances

State Regulations

California Proposition 65: This product does not contain any Proposition 65 chemicals.

15.2 Chemical safety assessment

No CSA has been conducted.
16. OTHER INFORMATION

Text of R phrases mentioned in Section 2
No information available

Revision Number: 5

The above information is based on data available to us and is believed to be correct. Since the information may be applied under conditions beyond our control and with which we may be unfamiliar, we do not assume any responsibility for the results of its use and all persons receiving it must make their own determination of the effects, properties and protections, which pertain to their particular conditions.

No representation, warranty, or guarantee, express or implied (including a warranty of fitness or merchantability for a particular purpose), is made with respect to the materials, the accuracy of this information, the results to be obtained from the use thereof, or the hazards connected with the use of the material. Caution should be used in the handling and use of the material because it may be biologically active.